Try our Advanced Search for more refined results

In Re: Pfizer Securities Litigation

  1. December 21, 2016

    Celebrex Judge OKs $468M Settlement, $130M In Fees

    Attorneys representing a certified class in a long-running multidistrict litigation against Pfizer Inc. got everything on their Christmas list Wednesday when a New York federal judge gave final approval to a $468 million settlement and approved more than $150 million in attorneys' fees and litigation expenses.

  2. September 19, 2016

    Judge OKs $486M Celebrex, Bextra Securities MDL Deal

    A New York federal judge on Friday preliminarily approved Pfizer Inc.'s $486 million settlement resolving long-running multidistrict litigation accusing the company of misleading investors about the alleged risks of its pain treatments Celebrex and Bextra and set a final approval hearing for Dec. 21.

  3. August 02, 2016

    Pfizer To Pay $486M To Settle Celebrex, Bextra Securities MDL

    Pfizer Inc. will pay $486 million to settle long-running multidistrict litigation accusing it of misleading investors about the alleged risks of its pain treatments Celebrex and Bextra, according to an earnings report the pharmaceutical company filed Tuesday.

  4. May 23, 2014

    Pfizer Investor Suit Hits Roadblock As Expert Report Tossed

    A long-running securities class action alleging Pfizer Inc. hid health risks associated with painkiller drugs faces an uncertain future after a New York federal judge threw out a crucial damages report by the plaintiffs' expert witness.

  5. May 22, 2014

    Ex-Pfizer Execs Can't Duck Class Action Over Celebrex Risks

    A New York federal judge on Thursday declined to free two former Pfizer Inc. executives from a long-running securities class action accusing the pharmaceutical giant of concealing serious health risks associated with blockbuster painkillers Celebrex and Bextra. 

  6. March 29, 2013

    Pfizer Can't Shake Securities Action Over Celebrex Risks

    A New York federal judge on Thursday trimmed a long-running securities class action accusing Pfizer Inc. of concealing serious health risks associated with blockbuster painkillers Celebrex and Bextra, but ruled the bulk of the plaintiff's allegations were strong enough to advance.

  7. January 08, 2013

    Pfizer, Investors Lose Sanctions Bids In Arthritis Drugs Case

    A New York magistrate judge on Tuesday rejected motions for sanctions by both Pfizer Inc. and shareholders in a securities class action over investor losses due to side effects of arthritis painkillers Celebrex and Bextra, saying neither side had proved evidence was destroyed.

  8. November 21, 2012

    Investors Say Pfizer Destroyed Files On Celebrex, Bextra

    Pfizer Inc. destroyed or concealed millions of pages of documents in hopes of undermining a securities class action over risks of arthritis drugs Celebrex and Bextra and should be sanctioned, investors told a New York federal judge Friday.

  9. March 30, 2012

    Investor Class Certified On Claims Pfizer Masked Drug Risks

    A New York federal judge on Thursday certified a class of Pfizer Inc. investors accusing the pharmaceutical giant of securities fraud for allegedly concealing studies showing the heart attack risks linked to arthritis drugs Celebrex and Bextra.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!